Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Simulations Plus ( (SLP) ) has provided an update.
Simulations Plus reported a strong start to fiscal 2025 with a 31% increase in total revenue for the first quarter, primarily driven by a 41% growth in software revenue. The company noted significant contributions from its MonolixSuite and Quantitative Systems Pharmacology business units, despite facing temporary headwinds in services revenue. Management expressed optimism for continued momentum in the latter half of the year, aligning with their fiscal guidance for 2025.
More about Simulations Plus
Simulations Plus is a leading provider in the biopharma sector, offering advanced software and consulting services that enhance various stages of drug development, including discovery, clinical trial operations, and commercialization. Their solutions integrate AI/ML, pharmacokinetics, biopharmaceutics, and modeling approaches, and are licensed by top pharmaceutical, biotechnology, and regulatory agencies worldwide.
YTD Price Performance: 4.26%
Average Trading Volume: 209,948
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $584.5M
For a thorough assessment of SLP stock, go to TipRanks’ Stock Analysis page.
